Literature DB >> 15714047

Safety and efficacy of GABAergic medications for treating alcoholism.

Bankole A Johnson1, Robert M Swift, Giovanni Addolorato, Domenic A Ciraulo, Hugh Myrick.   

Abstract

This article highlights the proceedings of a symposium presented at the 27th Annual Scientific Meeting of the Research Society on Alcoholism in Vancouver, British Columbia, Canada, June 29, 2004. The organizers and co-chairs were Bankole A. Johnson, MD, PhD, and Robert M. Swift, MD, PhD. The presentations included (1) Introduction, by Bankole A. Johnson; (2) Safety, Tolerability, and Efficacy of gamma-Hydroxybutyric Acid and Baclofen in the Treatment of Alcohol Addiction, by Giovanni Addolorato; (3) Safety of Gabapentin in Treating Alcoholism, by Hugh Myrick; (4) New Data on the Safety and Effectiveness of Topiramate in the Treatment of Alcohol Dependence, by Bankole A. Johnson; (5) Evaluating the Risk of Benzodiazepine Prescription to Alcohol-Dependent Individuals, by Domenic A. Ciraulo; and (6) Safety and Efficacy of GABAergic Agents in Treating Alcoholics: Discussion, by Robert M. Swift.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15714047     DOI： 10.1097/01.alc.0000153542.10188.b0

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN： 0145-6008            Impact factor:   3.455


  22 in total

Review 1.  Introduction to behavioral addictions.

Authors:  Jon E Grant; Marc N Potenza; Aviv Weinstein; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2010-09       Impact factor: 3.829

2.  Neurosteroid modulators of GABA(A) receptors differentially modulate Ethanol intake patterns in male C57BL/6J mice.

Authors:  Matthew M Ford; Jeffrey D Nickel; Tamara J Phillips; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2005-09       Impact factor: 3.455

3.  Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.

Authors:  Nathalie Pross; Alain Patat; Philippe Vivet; Michelle Bidaut; Nicolas Fauchoux
Journal:  Br J Clin Pharmacol       Date:  2015-08-11       Impact factor: 4.335

Review 4.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 5.  Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism.

Authors:  Roberto Ciccocioppo; Daina Economidou; Andrea Cippitelli; Marino Cucculelli; Massimo Ubaldi; Laura Soverchia; Anbarasu Lourdusamy; Maurizio Massi
Journal:  Addict Biol       Date:  2006-09       Impact factor: 4.280

Review 6.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

7.  Forensic toxicology findings in deaths involving gamma-hydroxybutyrate.

Authors:  Fredrik C Kugelberg; Anita Holmgren; Arne Eklund; Alan Wayne Jones
Journal:  Int J Legal Med       Date:  2008-12-02       Impact factor: 2.686

8.  The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

Authors:  Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2009-04-23       Impact factor: 4.492

9.  Acute interaction of baclofen in combination with alcohol in heavy social drinkers.

Authors:  Suzette M Evans; Adam Bisaga
Journal:  Alcohol Clin Exp Res       Date:  2008-10-06       Impact factor: 3.455

Review 10.  Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.

Authors:  Fabio Caputo; Teo Vignoli; Icro Maremmani; Mauro Bernardi; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2009-06-24       Impact factor: 3.390
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.